SC
FTH

Stempoint Capital’s Faeth Therapeutics FTH Stock Holding History

Stempoint Capital’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-132,873
Closed -$4.19M – 107
2026
Q1 		$4.19M Buy
+132,873
New +$2.65M 0.8% 39

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Stempoint Capital's FTH Position: Q2 2026 in Review

Stempoint Capital sold out of Faeth Therapeutics (FTH) in Q2 2026, closing a stake of 132,873 shares — an estimated $4.19M sold.

Stempoint Capital first reported a position in FTH in Q1 2026 and held it in 1 quarter. The position peaked at $4.19M in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Stempoint Capital reported no remaining Faeth Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 132,873 Faeth Therapeutics shares in Q2 2026, an estimated $4.19M.
  • Stempoint Capital first reported a position in Faeth Therapeutics in Q1 2026 and held it in 1 quarter.
  • Stempoint Capital's Faeth Therapeutics position peaked at $4.19M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.